Mean Arterial Pressure and Neonatal Outcomes in Pregnancies Complicated by Mild Chronic Hypertension
Authors: Moore Matthew D. , Kuo Hui-Chien , Sinkey Rachel G. , Boggess Kim , Dugoff Lorraine , Sibai Baha , Lawrence Kirsten , Hughes Brenna L. , Bell Joseph , Aagaard Kjersti , Edwards Rodney K. , Gibson Kelly S. , Haas David M. , Plante Lauren , Metz Torri D. , Casey Brian , Esplin Sean , Longo Sherri , Hoffman Matthew K. , Saade George R. , Hoppe Kara K. , Foroutan Janelle , Tuuli Methodius , Owens Michelle Y. , Simhan Hyagriv N. , Frey Heather A. , Rosen Todd , Palatnik Anna , Baker Susan , August Phyllis , Reddy Uma M. , Kinzler Wendy , Su Emily J. , Krishna Iris , Nguyen Nguyet A. , Norton Mary E. , Skupski Daniel , El-Sayed Yasser Y. , Ogunyemi Dotun , Librizzi Ronald , Pereira Leonardo , Magann Everett F. , Habli Mounira , Williams Shauna , Mari Giancarlo , Pridjian Gabriella , McKenna David S. , Parrish Marc , Chang Eugene , Osmundson Sarah , Quiñones Joanne N. , Leach Justin , Sanusi Ayodeji , Galis Zorina S. , Harper Lorie , Ambalavanan Namasivayam , Szychowski Jeff M. , Tita Alan T.N. 
Published: May 2024

OBJECTIVE:
To estimate the association between mean arterial pressure during pregnancy and neonatal outcomes in participants with chronic hypertension using data from the CHAP (Chronic Hypertension and Pregnancy) trial.

METHODS:
A secondary analysis of the CHAP trial, an open-label, multicenter randomized trial of antihypertensive treatment in pregnancy, was conducted. The CHAP trial enrolled participants with mild chronic hypertension (blood pressure [BP] 140–159/90–104 mm Hg) and singleton pregnancies less than 23 weeks of gestation, randomizing them to active treatment (maintained on antihypertensive therapy with a goal BP below 140/90 mm Hg) or standard treatment (control; antihypertensives withheld unless BP reached 160 mm Hg systolic BP or higher or 105 mm Hg diastolic BP or higher). We used logistic regression to measure the strength of association between mean arterial pressure (average and highest across study visits) and to select neonatal outcomes. Unadjusted and adjusted odds ratios (per 1-unit increase in millimeters of mercury) of the primary neonatal composite outcome (bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, or intraventricular hemorrhage grade 3 or 4) and individual secondary outcomes (neonatal intensive care unit admission [NICU], low birth weight [LBW] below 2,500 g, and small for gestational age [SGA]) were calculated.

RESULTS:
A total of 2,284 participants were included: 1,155 active and 1,129 control. Adjusted models controlling for randomization group demonstrated that increasing average mean arterial pressure per millimeter of mercury was associated with an increase in each neonatal outcome examined except NEC, specifically neonatal composite (adjusted odds ratio [aOR] 1.12, 95% CI, 1.09–1.16), NICU admission (aOR 1.07, 95% CI, 1.06–1.08), LBW (aOR 1.12, 95% CI, 1.11–1.14), SGA below the fifth percentile (aOR 1.03, 95% CI, 1.01–1.06), and SGA below the 10th percentile (aOR 1.02, 95% CI, 1.01–1.04). Models using the highest mean arterial pressure as opposed to average mean arterial pressure also demonstrated consistent associations.

CONCLUSION:
Increasing mean arterial pressure was positively associated with most adverse neonatal outcomes except NEC. Given that the relationship between mean arterial pressure and adverse pregnancy outcomes may not be consistent at all mean arterial pressure levels, future work should attempt to further elucidate whether there is an absolute threshold or relative change in mean arterial pressure at which fetal benefits are optimized along with maternal benefits.

CLINICAL TRIAL REGISTRATION:

ClinicalTrials.gov, NCT02299414.